392 related articles for article (PubMed ID: 10616013)
21. Local hyperemia to heating is impaired in secondary Raynaud's phenomenon.
Boignard A; Salvat-Melis M; Carpentier PH; Minson CT; Grange L; Duc C; Sarrot-Reynauld F; Cracowski JL
Arthritis Res Ther; 2005; 7(5):R1103-12. PubMed ID: 16207327
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.
Shenoy PD; Kumar S; Jha LK; Choudhary SK; Singh U; Misra R; Agarwal V
Rheumatology (Oxford); 2010 Dec; 49(12):2420-8. PubMed ID: 20837499
[TBL] [Abstract][Full Text] [Related]
23. Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon.
Marasini B; Casari S; Bestetti A; Maioli C; Cugno M; Zeni S; Turri O; Guagnellini E; Biondi ML
J Rheumatol; 2000 Nov; 27(11):2621-3. PubMed ID: 11093443
[TBL] [Abstract][Full Text] [Related]
24. Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial.
Sauza J; Kraus A; González-Amaro R; Alarcón-Segovia D
J Rheumatol; 1984 Jun; 11(3):362-4. PubMed ID: 6376801
[TBL] [Abstract][Full Text] [Related]
25. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study.
Finch MB; Dawson J; Johnston GD
Clin Rheumatol; 1986 Dec; 5(4):493-8. PubMed ID: 3816096
[TBL] [Abstract][Full Text] [Related]
26. Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: effect of cold exposure.
Cracowski JL; Carpentier PH; Imbert B; Cachot S; Stanke-Labesque F; Bessard J; Bessard G
Arthritis Rheum; 2002 May; 46(5):1319-23. PubMed ID: 12115239
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
[TBL] [Abstract][Full Text] [Related]
28. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
[TBL] [Abstract][Full Text] [Related]
29. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
Fries R; Shariat K; von Wilmowsky H; Böhm M
Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
[TBL] [Abstract][Full Text] [Related]
30. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
[TBL] [Abstract][Full Text] [Related]
31. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.
Herrick AL; van den Hoogen F; Gabrielli A; Tamimi N; Reid C; O'Connell D; Vázquez-Abad MD; Denton CP
Arthritis Rheum; 2011 Mar; 63(3):775-82. PubMed ID: 21360507
[TBL] [Abstract][Full Text] [Related]
32. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
[TBL] [Abstract][Full Text] [Related]
33. The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon.
Anderson ME; Moore TL; Lunt M; Herrick AL
Rheumatology (Oxford); 2007 Mar; 46(3):533-8. PubMed ID: 17018538
[TBL] [Abstract][Full Text] [Related]
34. Seasonal variation of Raynaud's phenomenon secondary to systemic sclerosis.
Watson HR; Robb R; Belcher G; Belch JJ
J Rheumatol; 1999 Aug; 26(8):1734-7. PubMed ID: 10451070
[TBL] [Abstract][Full Text] [Related]
35. Erectile dysfunction associated with scleroderma: a case-control study of men with scleroderma and rheumatoid arthritis.
Hong P; Pope JE; Ouimet JM; Rullan E; Seibold JR
J Rheumatol; 2004 Mar; 31(3):508-13. PubMed ID: 14994396
[TBL] [Abstract][Full Text] [Related]
36. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
Nguyen VA; Eisendle K; Gruber I; Hugl B; Reider D; Reider N
Rheumatology (Oxford); 2010 Mar; 49(3):583-7. PubMed ID: 20040526
[TBL] [Abstract][Full Text] [Related]
37. In vivo study of skin mechanical properties in Raynaud's phenomenon.
Dobrev H
Skin Res Technol; 2007 Feb; 13(1):91-4. PubMed ID: 17250538
[TBL] [Abstract][Full Text] [Related]
38. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
Colakoğlu M; Cobankara V; Akpolat T
Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
[TBL] [Abstract][Full Text] [Related]
39. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes.
Vayssairat M
J Rheumatol; 1996 Nov; 23(11):1917-20. PubMed ID: 8923366
[TBL] [Abstract][Full Text] [Related]
40. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
Surwit RS; Gilgor RS; Allen LM; Duvic M
Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
